NASDAQ:PACBPacific Biosciences of California Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Pacific Biosciences of California Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.91 -0.07 (-2.35 %) (As of 04/7/2020 01:39 PM ET) Add Compare Share Today's Range$2.89Now: $2.91▼$3.0950-Day Range$2.36MA: $3.39▼$4.5752-Week Range$2.20Now: $2.91▼$7.50Volume1.46 million shsAverage Volume2.37 million shsMarket Capitalization$445.61 millionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, Africa, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingPacific Biosciences of California has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Pacific Biosciences of California has a potential upside of 106.2% from its current price of $2.91.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 1 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesPacific Biosciences of California has received 407 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPacific Biosciences of California has received 331 “underperform” votes. (Add your “underperform” vote.)Community SentimentPacific Biosciences of California has received 55.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote “Outperform” if you believe PACB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,448,517.00 in company stock.Percentage Held by InsidersOnly 11.60% of the stock of Pacific Biosciences of California is held by insiders.Percentage Held by Institutions75.23% of the stock of Pacific Biosciences of California is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pacific Biosciences of California are expected to decrease by -5.08% in the coming year, from ($0.59) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -5.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 8.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB Previous Symbol CUSIP69404D10 CIK1299130 Webhttp://www.pacb.com/ Phone650-521-8000Debt Debt-to-Equity Ratio0.76 Current Ratio1.65 Quick Ratio1.38Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$90.89 million Price / Sales4.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book8.08Profitability EPS (Most Recent Fiscal Year)($0.55) Net Income$-84,130,000.00 Net Margins-92.57% Return on Equity-121.70% Return on Assets-51.76%Miscellaneous Employees401 Outstanding Shares153,130,000Market Cap$445.61 million Next Earnings Date5/1/2020 (Estimated) OptionableOptionable Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PACB Rates by TradingView Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions How has Pacific Biosciences of California's stock been impacted by COVID-19 (Coronavirus)? Pacific Biosciences of California's stock was trading at $3.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PACB shares have decreased by 15.4% and is now trading at $2.91. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Pacific Biosciences of California? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacific Biosciences of California. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Pacific Biosciences of California. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.04. The biotechnology company earned $21.92 million during the quarter, compared to analysts' expectations of $28.02 million. Pacific Biosciences of California had a negative net margin of 92.57% and a negative return on equity of 121.70%. View Pacific Biosciences of California's earnings history. What price target have analysts set for PACB? 2 brokers have issued 12-month price objectives for Pacific Biosciences of California's shares. Their forecasts range from $5.00 to $7.00. On average, they expect Pacific Biosciences of California's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 106.2% from the stock's current price. View analysts' price targets for Pacific Biosciences of California. What are Wall Street analysts saying about Pacific Biosciences of California stock? Here are some recent quotes from research analysts about Pacific Biosciences of California stock: 1. According to Zacks Investment Research, "Pacific Biosciences has been gaining ground in the MedTech space on strong Sequel performance. The company’s product revenues also shot up in recent times. Meanwhile, one of Pacific Biosciences’ biggest rival — Illumina — recently announced the termination of the formerly announced $1.20 billion-merger agreement. Per management, Illumina will be paying Pacific Biosciences a termination fee of $98 million. Expansion in gross margin in recent times is also a positive. On the flip side, significant rise in operating expenses remains concerning. The company’s loss per share remained flat year over year. The DNA sequencing market is fraught with competition. The stock has underperformed its industry in a year’s time and is overvalued at the moment." (1/7/2020) 2. Cantor Fitzgerald analysts commented, "We think PACB’s long-read next-generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. The company has seen mixed revenue performance over the past three years, but we think PACB is getting close to an inflection point, which we think the Street is missing. We see the path to revenue acceleration as multifactorial. These include the launch of its 8 million ZMW SMRT cell, increased penetration of the plant and animal sequencing market, and significant sequencing cost reduction per human genome enabling PACB to become a more mainstream player in human genomics." (5/3/2019) Has Pacific Biosciences of California been receiving favorable news coverage? Press coverage about PACB stock has trended very negative on Tuesday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pacific Biosciences of California earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPacific Biosciences of California. Are investors shorting Pacific Biosciences of California? Pacific Biosciences of California saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 21,266,400 shares, an increase of 19.1% from the February 27th total of 17,860,000 shares. Based on an average daily trading volume, of 2,755,100 shares, the days-to-cover ratio is presently 7.7 days. Approximately 15.3% of the shares of the stock are sold short. View Pacific Biosciences of California's Current Options Chain. Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD). What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Novavax (NVAX), Illumina (ILMN), Sangamo Therapeutics (SGMO), Crispr Therapeutics (CRSP), Gilead Sciences (Gild), FireEye (FEYE), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the following people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 70)Ms. Susan K. Barnes, Exec. VP & CFO (Age 65)Mr. James Michael Phillips, Sr. VP of R&D (Age 68)Dr. Stephen Turner, Co-Founder & CTO (Age 51)Dr. Jonas Korlach Ph.D., Chief Scientific Officer What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $2.91. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $445.61 million and generates $90.89 million in revenue each year. The biotechnology company earns $-84,130,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Pacific Biosciences of California employs 401 workers across the globe. View additional information about Pacific Biosciences of California. What is Pacific Biosciences of California's official website? The official website for Pacific Biosciences of California is http://www.pacb.com/. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: What is a Derivative?
